You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Avatar Assisted Therapy for Probationers and Parolees with Substance Use Disorders
SBC: COG ANALYTICS, LLC Topic: 102DESCRIPTION provided by applicant Substance use disorders SUDs continue to be one of the most serious public health problems in the US Studies have consistently documented a substantially higher prevalence of SUDs among individuals under criminal justice supervision At year end approximately million adults were under criminal justice supervision in the US of which million i ...
STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health -
Rational design of small interfering RNA for genome-wide target knockdown
SBC: Nawgen, LLC Topic: 172DESCRIPTION provided by applicant RNA interference RNAi is a small RNA guided gene silencing process within living cells The RNAi technique is widely used in both biological research and clinical applications because it has the ability to knockdown essentially any gene of interest However one major unresolved issue in RNAi studies is non specific gene silencing It is well known that in ...
STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health -
Electronic Optimization of Stem Cell Derived Human Cardiac Myocytes
SBC: Cytocybernetics Inc Topic: NHLBIDESCRIPTION provided by applicant As part of the FDA approval process for novel therapeutic drugs safety screening demonstrating that the new drug does not have deleterious effects on the human cardiac action potential is required Healthy human heart cells are not available for such preclinical drug testing There is currently no consensus on the best experimental approach to provide the most ...
STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health -
Evaluation of TRB-N0224, a Proprietary Chemically Modified Curcumin, for the Treatment of Periodontal Disease in a LPS-Induced Rat Model
SBC: TRAVERSE BIOSCIENCES, INC. Topic: NIDCRDESCRIPTION provided by applicant Traverse Biosciences Inc is a pre clinical stage drug development company working to commercialize new chemical entities which act to resolve inflammatory conditions through pleiotropic host modulation of pathologically unrestrained matrix metalloproteinases MMPs and pro inflammatory cytokines The companyandapos s lead drug candidate TRB N is a propri ...
STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health -
Scientific Merit and Feasibility of Fructokinase Inhibiton for Obesity
SBC: COLORADO RESEARCH PARTNERS LLC Topic: NIDDKDESCRIPTION provided by applicant Intake of added sweeteners high fructose corn syrup and sucrose independently predicts the development of obesity metabolic syndrome and diabetes Despite recommendations by WHO and the AHA to reduce sugar intake to to percent of total energy intake the mean intake of added sugars remains percent of the diet and percent of the population ingest ...
STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health -
Speech Enhancement Based on Auditory Coding of Voiced Signals
SBC: OMNISPEECH, LLC Topic: NIDCDDESCRIPTION provided by applicant The greatest challenge to auditory communication is background noise especially in the complex acoustic environments that are experienced in daily life This project proposes to develop a novel speech enhancement algorithm that is robust in the presence of everyday environmental interference The algorithm is inspired by recent findings related to the neural c ...
STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health -
A Low Cost, Quantitative, Chemical Specific Device for Illicit Drug Detection
SBC: MKS Technology Topic: NIDADESCRIPTION provided by applicant This proposal will assess the quantitative capabilities of surface enhanced Raman scattering SERS detection of cocaine and marijuana metabolites in urine samples Combining low cost instrumentation and novel chemical sensing provides an innovative new approach for diagnosing illicit drug use Current methods use a colorimetric indicator to screen specimens fo ...
STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health -
Development of a high-throughput assay for measuring m6A demethylase activity
SBC: Base5 Biosciences Inc Topic: NIDADESCRIPTION provided by applicant N methyladenosine m A was recently discovered to be a widespread base modification present in thousands of mammalian mRNAs In addition to its prevalence throughout the transcriptome researchers have also revealed that m A is a reversible modification suggesting that dynamic regulation of mRNA methylation is a novel and widespread RNA regulatory mechanism ...
STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health -
Technology-Guided Opioid Cessation for Post-Operative Pain
SBC: MedicaSafe Inc Topic: R41DESCRIPTION provided by applicant This STTR application proposes development of MedicaSafe Inc andapos s Multimodal Analgesic Protection System MAPSafe Built around MedicaSafeandapos s proprietary Medication Therapy Optimization MTO technology MAPSafe will be designed to mitigate the myriad risks associated with prescription opioid use post operatively and throughout recovery after surge ...
STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health -
Manufacturing pathogen inactivated platelet lysate to treat corneal inflammation
SBC: Cambium Medical Technologies LLC Topic: NDESCRIPTION provided by applicant Ocular graft versus host disease O GVHD is a particularly severe and debilitating complication of allogeneic hematopoietic stem cell transplantation HSCT O GVHD develops in of patients with chronic GVHD Currently Restasis cyclosporine A is the only FDA approved prescription topical medication to treat O GVHD In Restasis had sales o ...
STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health